any thoughts???, page-18

From todays announcement...

Avexa completes recruitment for first stage of ATC phase 3. Lets hope a partner sees it this way. Every step forward counts....feels like baby steps.

Recruitment completion of the two-dose component of the Phase III trial further de-risks the
program and adds significant value to ATC on our road to commercialisation of the compound,”
said Dr Julian Chick, Chief Executive Officer of Avexa. “As evidenced in our extension study,
ATC has a very strong safety profile, an unusually low level of resistance development, and an
excellent antiviral activity profile against difficult-to-treat, drug-resistant HIV. The length of time
that some of our patients have elected to remain on ATC validates its potential to be a robust,
long-term component of any HIV treatment regimen.”